Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Abstract:

:Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development of early detection methods, such as serial measurements of EBV-DNA load in the peripheral blood of transplant recipients. Immunotherapeutic interventions for EBV-LPD include reduction of immunosuppression, CD20 monoclonal antibodies (rituximab) as monotherapy or in conjunction with chemotherapy, and adoptive immunotherapy with EBV-specific T cells. Pre-emptive immunotherapeutic interventions can prevent the development of EBV-LPD. As monotherapy, immunotherapy is effective in inducing remissions of EBV-LPD with low-risk features. For high-risk disease, combining immunotherapy with conventional therapies has led to superior outcomes. Current challenges consist of risk stratifying patients so that patients receive the most efficacious therapy without suffering from unwanted side effects.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Shaffer DR,Rooney CM,Gottschalk S

doi

10.2217/imt.10.43

subject

Has Abstract

pub_date

2010-09-01 00:00:00

pages

663-71

issue

5

eissn

1750-743X

issn

1750-7448

journal_volume

2

pub_type

杂志文章,评审
  • Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 2011, Barcelona, Spain.

    abstract::The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...

    journal_title:Immunotherapy

    pub_type: 总体

    doi:10.2217/imt.11.90

    authors: Shore ND

    更新日期:2011-08-01 00:00:00

  • Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.

    abstract::Rheumatoid arthritis (RA) is a chronic inflammatory disease in which persistent inflammation of synovial tissue results in a progressive functional decline of the joint and premature mortality. TNF inhibitors were the first biological disease-modifying antirheumatic drugs (DMARDs) used to treat RA. Since then, new bio...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.26

    authors: García-Hernández MH,González-Amaro R,Portales-Pérez DP

    更新日期:2014-01-01 00:00:00

  • Carnitine deficiency and its possible risk factors in TB patients: first report.

    abstract:AIM:To assess carnitine serum levels and possible risk factors of its deficiency in patients with TB. PATIENTS & METHODS:All newly diagnosed TB patients admitted to an infectious diseases ward were recruited. Demographic, clinical and paraclinical characteristics of the patients were collected. Total carnitine serum c...

    journal_title:Immunotherapy

    pub_type: 临床试验,杂志文章

    doi:10.2217/imt.13.90

    authors: Hatamkhani S,Khalili H,Karimzadeh I,Abdollahi A,Jafari S,Khazaeipour Z

    更新日期:2013-09-01 00:00:00

  • Genetic modification of natural killer cells for adoptive cellular immunotherapy.

    abstract::Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.36

    authors: Pegram HJ,Kershaw MH,Darcy PK

    更新日期:2009-07-01 00:00:00

  • Adjuvant immunotherapies as a novel approach to bacterial infections.

    abstract::The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.17

    authors: Helbig ET,Opitz B,Sander LE

    更新日期:2013-04-01 00:00:00

  • An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.

    abstract::In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is asso...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0235

    authors: Filgueira LM,Cervantes JB,Lovelle OA,Herrera C,Figueredo C,Caballero JA,Sánchez N,Berrio J,Lorenzo G,Cepeda M,Ramos M,Saavedra D,Añe-Kouri AL,Mazorra Z,Leon K,Crombet T,Caballero A

    更新日期:2021-03-01 00:00:00

  • Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients.

    abstract::In recent years, there have been reports of immunotherapy inducing objective clinical responses in limited numbers of cancer patients. More frequently, however, clinical responses are not observed. Understanding the immunological mechanisms underlying successful immunotherapy are crucial if the field is to move forwar...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.11.62

    authors: Hardwick N,Chain B

    更新日期:2011-06-01 00:00:00

  • Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients.

    abstract::Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011). Chimeric antigen receptor (CAR)-T cells are promising antitumor immunotherapies. However, there are limit...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.11.135

    authors: Gandhi M,Jones K

    更新日期:2011-12-01 00:00:00

  • Immunotherapy targeting colon cancer stem cells.

    abstract::In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinic...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.87

    authors: Iovino F,Meraviglia S,Spina M,Orlando V,Saladino V,Dieli F,Stassi G,Todaro M

    更新日期:2011-01-01 00:00:00

  • Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.

    abstract::Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0154

    authors: Cala-García JD,Sierra-Bretón JD,Cavelier-Baiz JE,Faccini-Martínez ÁA,Pérez-Díaz CE

    更新日期:2020-10-01 00:00:00

  • Dendritic cell vaccines targeting survivin in head and neck cancer.

    abstract::Evaluation of: Turksma AW, Bontkes HJ, Ruizendaal JJ et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J. Transl. Med. 11, 152-165 (2013). Survivin has been identified to be an inhibitor of apoptosis and is highly expressed in many cancers. A number o...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.120

    authors: Lee WT

    更新日期:2013-11-01 00:00:00

  • Checkpoint inhibition in meningiomas.

    abstract::Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evide...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0017

    authors: Bi WL,Wu WW,Santagata S,Reardon DA,Dunn IF

    更新日期:2016-06-01 00:00:00

  • Immune modulation by apoptotic dental pulp stem cells in vivo.

    abstract::Mesenchymal stem cells (MSCs) show considerable promise as a cellular immunotherapy for the treatment of a number of autoimmune and inflammatory disorders. However, the precise physiologically and therapeutically relevant mechanism(s) by which MSCs mediate immune modulation remains elusive. Dental pulp stem cells are ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0117

    authors: Laing AG,Riffo-Vasquez Y,Sharif-Paghaleh E,Lombardi G,Sharpe PT

    更新日期:2018-03-01 00:00:00

  • Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.

    abstract::Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.46

    authors: He Y,Hong Y,Mizejewski GJ

    更新日期:2014-01-01 00:00:00

  • γδ T cells as a potential tool in colon cancer immunotherapy.

    abstract::γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, t...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.59

    authors: Ramutton T,Buccheri S,Dieli F,Todaro M,Stassi G,Meraviglia S

    更新日期:2014-01-01 00:00:00

  • Jacalin regulates IgA production by peripheral blood mononuclear cells.

    abstract:AIMS:In IgA nephropathy, circulating immune complexes containing IgA1 are deposited on the glomerular mesangium, causing mesangial cell proliferation and acceleration of extracellular matrix production. The suppressive effect of jacalin, a galactose-binding lectin, on IgA production in vitro was determined. MATERIALS ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.125

    authors: Miyamoto K,Chiba T,Shinohara N,Nagata Y,Asakawa N,Kato S,Mizutani N,Murata T,Nomura S,Horiuchi T

    更新日期:2012-12-01 00:00:00

  • Reslizumab for pediatric eosinophilic esophagitis.

    abstract::Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.10.41

    authors: Walsh GM

    更新日期:2010-07-01 00:00:00

  • Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?

    abstract::Sarcoidois is an inflammatory disease of unknown origin characterized by the abnormal accumulation of noncaseating granulomas at sites of disease activity in multiple organs throughout the body with a predilection for the lungs. Because the exact trigger that leads to disease activity is still under investigation, cur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.103

    authors: Celada LJ,Drake WP

    更新日期:2015-01-01 00:00:00

  • The role of the microbiome in childhood asthma.

    abstract::It is now well established that the healthy bronchial tree contains a microbiome distinct from that of the upper respiratory tract and that the lung microbiome may be dysregulated in individuals with a chronic respiratory disease, such as asthma. In addition, after birth, gut microbes interact with the host tissue, es...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0048

    authors: Pisi G,Fainardi V,Aiello M,Bertorelli G,Crisafulli E,Chetta A

    更新日期:2017-11-01 00:00:00

  • Tolerogenic dendritic cells for Type 1 diabetes.

    abstract::Evaluation of: Pujol-Autonell I, Ampudia RM, Monge P et al. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice. ISRN Endocrinol. doi:10.1155/2013/346987 (2013) (Epub ahead of print). Many reports confirm that dendritic cells (DCs) can prevent aut...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.50

    authors: Giannoukakis N

    更新日期:2013-06-01 00:00:00

  • Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.

    abstract::Oncogenic signaling pathways have emerged as key targets for the development of small-molecule inhibitors, with several protein kinase inhibitors already in clinical use for cancer patients. In addition to their role in tumorigenesis, many of the molecules and signaling pathways targeted by these inhibitors are also i...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.99

    authors: Ott PA,Adams S

    更新日期:2011-02-01 00:00:00

  • The immunoreactivity of the anti-p21Ras single-chain fragment variant KGH-R1 and its predicted binding sites to p21Ras.

    abstract::Aim: Previously, we constructed a novel anti-p21Ras single-chain antibody fragment, KGH-R1-single-chain fragment variant (ScFv). However, the immunoreactivity of this antibody toward p21Ras is still unclear. Materials & methods: ELISAs, immunohistochemistry, western blotting and immunofluorescence were used to identif...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0222

    authors: Wang P,Pan X,Feng Q,Zou H,Cui J,He Y,Luo Y,Yang J

    更新日期:2020-08-01 00:00:00

  • Non-coding RNA and immune-checkpoint inhibitors: friends or foes?

    abstract::Non-coding RNAs (ncRNAs) are an abundant component of the human transcriptome. Their biological role, however, remains incompletely understood. Nevertheless, ncRNAs are highly associated with cancer development and progression due to their ability to modulate gene expression, protein translation and growth pathways. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0204

    authors: Shek D,Read SA,Akhuba L,Qiao L,Gao B,Nagrial A,Carlino MS,Ahlenstiel G

    更新日期:2020-05-01 00:00:00

  • Passive immune neutralization strategies for prevention and control of influenza A infections.

    abstract::Although vaccination significantly reduces influenza severity, seasonal human influenza epidemics still cause more than 250,000 deaths annually. Vaccine efficacy is limited in high-risk populations such as infants, the elderly and immunosuppressed individuals. In the event of an influenza pandemic (such as the 2009 H1...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.167

    authors: Ye J,Shao H,Perez DR

    更新日期:2012-02-01 00:00:00

  • The safety profile of Polyoxidonium in daily practice: results from postauthorization safety study in Slovakia.

    abstract:AIM:This study assessed the safety of Polyoxidonium® 6 mg lyophilisate for solution for injection in routine practice with a special focus on signs or symptoms of potential adverse renal effects. MATERIALS & METHODS:A local, multicenter, prospective, open-label, noninterventional, uncontrolled postauthorization safety...

    journal_title:Immunotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.2217/imt-2017-0116

    authors: Pružinec P,Chirun N,Sveikata A

    更新日期:2018-02-01 00:00:00

  • Modulatory effects of bortezomib on host immune cell functions.

    abstract::Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.66

    authors: Pellom ST Jr,Dudimah DF,Thounaojam MC,Sayers TJ,Shanker A

    更新日期:2015-01-01 00:00:00

  • Designing two-in-one antibodies.

    abstract::Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.09.39

    authors: Valladares IG,Espinoza LR

    更新日期:2009-09-01 00:00:00

  • Effect of inhaled inactivated Mycobacterium phlei in children with moderate asthma.

    abstract::Bacillus Calmette-Guérin and other mycobacterial vaccines are important therapeutic methods in a series of chronic inflammatory disorders characterized by Th1/Th2 imbalance in which Th2 type cells and cytokines often increase. However, few studies have investigated whether it can reduce or prevent the symptoms and att...

    journal_title:Immunotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.2217/imt.12.156

    authors: Ming M,Li C,Luo Z,Lv S

    更新日期:2013-02-01 00:00:00

  • Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.

    abstract::Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0266

    authors: Moreau P,Hebraud B,Facon T,Leleu X,Hulin C,Hashim M,Hu Y,Caillot D,Benboubker L,Zweegman S,Merz M,Weisel K,Salwender H,Mai EK,Goldschmidt H,Bertsch U,Vanquickelberghe V,Kampfenkel T,Boer C,Krotneva S,Proskorovsky

    更新日期:2021-02-01 00:00:00

  • Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors.

    abstract::Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.7

    authors: Smith C,Khanna R

    更新日期:2015-01-01 00:00:00